

## Private placement regarding Cryo Management fully subscribed

**The Extraordinary General Meeting of Vitrolife held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. In accordance with the resolution, the board of directors of Vitrolife has resolved to determine that the company's share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares. The new share issue was fully subscribed.**

The Extraordinary General Meeting of Vitrolife held September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. The board of directors of Vitrolife was authorized to make a decision regarding the highest amount that the company's share capital may be increased by, the highest number of shares that may be issued and what amount is to be paid for each new share. It was decided that the new shares were to be issued at a subscription price per share corresponding to the average closing price for Vitrolife's shares during the fifteen trading days immediately subsequent to the Vitrolife's shares being traded exclusive of entitlement to distribution of shares in Xvivo Perfusion AB, based on an average EUR/SEK exchange rate during the aforesaid fifteen trading days.

The board of directors has resolved to determine that the company's share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares and that the subscription price for each share shall be EUR 5.0428 based on an average closing price of 43,29 and an average EUR/SEK exchange rate of 8,5852.

The new share issue, which was directed to the previous owners of Cryo, was fully subscribed. Payment for the new shares was made by way of set-off of claims that the subscribers had on Vitrolife as a consequence of Vitrolife's acquisition of Cryo.

The new issued shares are estimated to be registered at Euroclear Sweden AB during November. After the new share issue is finalized, the total number of shares in Vitrolife AB is estimated to 19.830.936.

October 31, 2012  
VITROLIFE AB (publ)  
Thomas Axelsson, CEO

### Queries should be addressed to:

Thomas Axelsson, CEO, phone +46 31 721 80 01  
Mikael Engblom, CFO, phone +46 31 721 80 14

---

Vitrolife is a global biotechnology/medical device Group. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in ca 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com)

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 31, 2012 at 5:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.